We are live on !
Find out more
Great Point Partners Portfolio holdings
AUM
$529M
Turnover
44.44%
1-Year Est. Return
337.4%
This Fund
S&P 500
This Quarter Est. Return
+27.32%
1 Year Est. Return
+337.4%
3 Year Est. Return
+710.06%
5 Year Est. Return
+1,177.67%
10 Year Est. Return
+20,064.23%
AUM
$529M
AUM Growth
+$94M
(+22%)
Cap. Flow
-$41.6M
Cap. Flow % of AUM
Cap. Flow %
-7.87%
Top 10 Holdings %
Top 10 Hldgs %
51.64%
Holding
54
New
12
Increased
7
Reduced
10
Closed
12
Avg Time Held
Equity + Options
0.4
years
Top 10 Avg Time Held
Equity + Options
0.2
years
Top 20 Avg Time Held
Equity + Options
0.4
years
Avg Time Held Equity only
0.5
years
Top 10 Avg Time Held Equity only
0.2
years
Top 20 Avg Time Held Equity only
0.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abivax
ABVX
|
+$23.1M |
| 2 |
Vera Therapeutics
VERA
|
+$15M |
| 3 |
Sagimet Biosciences
SGMT
|
+$13.8M |
| 4 |
Definium Therapeutics
DFTX
|
+$10.5M |
| 5 |
Immix Biopharma
IMMX
|
+$8.61M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apogee Therapeutics
APGE
|
+$31.5M |
| 2 |
Amylyx Pharmaceuticals
AMLX
|
+$16.2M |
| 3 |
KalVista Pharmaceuticals
KALV
|
+$13.6M |
| 4 |
Immunovant
IMVT
|
+$13.6M |
| 5 |
Jade Biosciences
JBIO
|
+$13.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 78.18% |
| 2 | Miscellaneous | 19.78% |
| 3 | Financials | 2.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
CALL
Abivax
ABVX
$7.68B
| $53.3M | 10.07% |
+400,000
| New | +$45.3M |
2026 Q2
0 quarters
|
|
2
Vor Biopharma
VOR
$1.08B
| $31.3M | 5.91% |
1,700,000
-50,000
| -3% | -$757K |
2025 Q4
2 quarters
|
|
|
3
Abivax
ABVX
$7.68B
| $27.2M | 5.15% |
+204,314
| New | +$23.1M |
2026 Q2
0 quarters
|
|
4
PUT
ImmunityBio
IBRX
$8.71B
| $26.3M | 4.97% |
3,000,800
| – | – |
2026 Q1
1 quarter
|
|
|
5
Vera Therapeutics
VERA
$2.02B
| $25.8M | 4.87% |
600,836
+401,488
| +201% | +$15M |
2026 Q1
1 quarter
|
|
6
Zura Bio
ZURA
$322M
| $24.9M | 4.7% |
4,215,930
| – | – |
2023 Q2
12 quarters
|
|
7
Alumis Inc
ALMS
$878M
| $24.1M | 4.55% |
856,061
| – | – |
2026 Q1
1 quarter
|
|
8
Sol-Gel Technologies
SLGL
$227M
| $20.3M | 3.84% |
274,363
| – | – |
2026 Q1
1 quarter
|
|
9
PUT
Ultragenyx Pharmaceutical
RARE
$1.54B
| $20M | 3.79% |
+600,000
| New | +$14.9M |
2026 Q2
0 quarters
|
|
|
10
Definium Therapeutics
DFTX
$4.79B
| $20M | 3.78% |
+425,000
| New | +$10.5M |
2026 Q2
0 quarters
|
|
11
Annexon
ANNX
$711M
| $20M | 3.78% |
3,500,000
+1,000,000
| +40% | +$5.53M |
2026 Q1
1 quarter
|
|
12
Oruka Therapeutics
ORKA
$5.31B
| $17.4M | 3.3% |
183,330
| – | – |
2025 Q3
3 quarters
|
|
13
MoonLake Immunotherapeutics
MLTX
$1.01B
| $16.7M | 3.15% |
855,813
+355,813
| +71% | +$6.45M |
2026 Q1
1 quarter
|
|
|
14
Sagimet Biosciences
SGMT
$679M
| $15.7M | 2.97% |
+2,029,933
| New | +$13.8M |
2026 Q2
0 quarters
|
|
15
Contineum Therapeutics
CTNM
$313M
| $15.1M | 2.85% |
921,481
+121,283
| +15% | +$1.59M |
2025 Q4
2 quarters
|
|
|
16
Immix Biopharma
IMMX
$676M
| $13.2M | 2.49% |
1,277,642
+927,642
| +265% | +$8.61M |
2026 Q1
1 quarter
|
|
17
Climb Bio
CLYM
$585M
| $13M | 2.46% |
1,000,000
-334,130
| -25% | -$3.45M |
2025 Q4
2 quarters
|
|
|
18
Amylyx Pharmaceuticals
AMLX
$3.41B
| $12.6M | 2.38% |
700,000
-1,050,000
| -60% | -$16.2M |
2025 Q1
5 quarters
|
|
19
Nektar Therapeutics
NKTR
$1.27B
| $12.2M | 2.31% |
175,000
-141,453
| -45% | -$10.4M |
2025 Q3
3 quarters
|
|
20
Neurogene
NGNE
$471M
| $11.1M | 2.09% |
352,180
-147,820
| -30% | -$4.07M |
2023 Q4
10 quarters
|
|
21
LB Pharmaceuticals
LBRX
$1.25B
| $10.3M | 1.95% |
317,221
+17,221
| +6% | +$506K |
2026 Q1
1 quarter
|
|
22
Opus Genetics
IRD
$289M
| $8.1M | 1.53% |
1,970,187
+1,645,847
| +507% | +$7.68M |
2026 Q1
1 quarter
|
|
23
Eupraxia Pharmaceuticals
EPRX
$454M
| $7.93M | 1.5% |
1,200,000
| – | – |
2025 Q3
3 quarters
|
|
24
Bright Minds Biosciences
DRUG
$518M
| $7.69M | 1.45% |
109,603
-110,397
| -50% | -$8.67M |
2026 Q1
1 quarter
|
|
25
InflaRx
IFRX
$230M
| $6.82M | 1.29% |
+3,046,557
| New | +$5.72M |
2026 Q2
0 quarters
|
|
Similar funds
GECH
Great Point Partners's Q2 2026 Portfolio in Review
As of Q2 2026, Great Point Partners held 54 positions worth $529M, up 22% from $435M the previous quarter. Its ten largest holdings account for 52% of the portfolio.
Great Point Partners withdrew a net $41.6M in Q2 2026, closing 12 positions and reducing 10 holdings. Its most notable exit was Apogee Therapeutics, an estimated $31.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 94% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Great Point Partners opened a new position in Abivax worth $27.2M.
- Great Point Partners's largest Q2 2026 buy was Abivax: 204,314 shares worth $27.2M.
- Great Point Partners added most to Vera Therapeutics in Q2 2026, an estimated $15M increase.
- Great Point Partners's biggest Q2 2026 reduction was Amylyx Pharmaceuticals, cutting an estimated $16.2M.
- Great Point Partners fully exited Apogee Therapeutics in Q2 2026, selling an estimated $31.5M.
- Great Point Partners's ten largest holdings make up 52% of its $529M portfolio in Q2 2026.
- Great Point Partners opened 12 new positions and closed 12 in Q2 2026.
- Great Point Partners's portfolio value rose 22% quarter-over-quarter to $529M.
Based on Great Point Partners's 13F filing for Q2 2026, filed 14 Aug 2026.